Raritan Pharmaceuticals, 8 Joanna Ct, East Brunswick, NJ 08816, US

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. The company s specialized sales force markets Abelcet, Oncaspar, Adagen and Depocyt in North America. In addition, it also receives royalties on sales of Peg-Intron, which is marketed by Schering-Plough Corporation, and Macugen, which is marketed by OSI Pharmaceuticals and Pfizer. The company s product-driven strategy includes a drug development program that leverages its proprietary technologies that includes a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Enzon Pharmaceuticals is headquartered in Bridgewater, N.J.